Search clinical trials for: TheraSphere

Total 63 results

Boston Scientific Corporation

Recruiting

First In Human Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device (VOYAGER)

Cancer | Prostate

United States
AstraZeneca

Recruiting

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)

Hepatocellular Carcinoma (HCC)

United States
Ochsner Health System
Boston Scientific Corporation

Recruiting

90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia (REALM)

Carcinoma, Hepatocellular

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Hepatocellular Carcinoma

United States
Boston Scientific Corporation

Recruiting

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM (FRONTIER)

Glioblastoma Multiforme | Recurrent Glioblastoma

United States
Boston Scientific Corporation
Biocompatibles UK Ltd

Recruiting

TheraSphere With Durvalumab and Tremelimumab for HCC (ROWAN)

Hepatocellular Carcinoma

United States, Spain, France
Boston Scientific Corporation

Recruiting

MANDARIN (S6371)

Inoperable Hepatocellular Carcinoma

China
Federation Francophone de Cancerologie Digestive

Recruiting

Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer (SIRTCI)

Metastatic Colorectal Cancer | MSS | pMMR | Immune Checkpoint Inhibitor | Internal Radiotherapy

France
University of Michigan Rogel Cancer Center
Department of Health and Human Services; National Institute for Biomedical...

Recruiting

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

Liver Malignancy

United States
Imperial College London
Biocompatibles UK Ltd, a BT International group company

Recruiting

TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets (ArTisaN)

Neuroendocrine Tumors | Liver Metastases

United Kingdom
Northwestern University
BTG International Inc.

Recruiting

Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia

Thrombocytopenia | Cirrhosis

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma...

United States
Boston Scientific Corporation
Biocompatibles UK Ltd

Active, not recruiting

Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC) (PROACTIF)

Hepatocellular Carcinoma

France
Ankara University
Boston Scientific Corporation

Completed

Transarterial Radioembolization (TARE) in COlorectal MEtastasis of Liver (TACOME)

Transarterial Radioembolization

Turkey
Boston Scientific Corporation

Completed

TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.

Hepatocellular Carcinoma

United States
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Terminated

Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection

Hepatocellular Carcinoma

United States
University of California, Irvine
BTG International Inc.

Approved for marketing

TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma (TheraSphere)

Hepatocellular Carcinoma | Primary Liver Cancer | Liver Neoplasm | Liver Cancer

United States
University of Louisville
MDS Pharma Services

Completed

TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC) (TheraSphere)

Hepatocellular Carcinoma

United States
Boston Scientific Corporation
Biocompatibles UK Ltd

Completed

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer (STOP-HCC)

Unresectable Hepatocellular Carcinoma

Korea, Republic of, United States, Spain, France, United Kingdom, Canada, Germany, Singapore, Netherlands, Belgium, Italy
Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

TheraSphere® For Treatment of Metastases in Liver

Colorectal Cancer | Colorectal Cancer Metastatic

United States
Seoul National University Hospital

Completed

Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC (SOLID)

Hepatocellular Carcinoma

Korea, Republic of
Ashwin Somasundaram
Merck Sharp & Dohme LLC; Hoosier Cancer Research Network

Active, not recruiting

Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

Hepatocellular Carcinoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Withdrawn

Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma...

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Boston Scientific Corporation

Completed

Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option (Y-90HDE)

Liver Cancer | Hepatoma
Ohio State University Comprehensive Cancer Center

Completed

Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
BTG International Inc.; Biocompatibles UK Ltd

No longer available

Therasphere for Unresectable Primary or Secondary Liver Neoplasia

Liver Neoplasms | Liver Cancer | HepatoCellular Carcinoma

United States
IRCCS San Raffaele

Completed

Defibrotide in COVID-19 Pneumonia (DEFI-VID19)

Patients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure

Italy
Wake Forest University Health Sciences

Completed

HDE Use Protocol of TheraSphere for Treatment of Unresectable HCC

Hepatocellular Carcinoma
Boston Scientific Corporation
Biocompatibles UK Ltd

Completed

Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer (EPOCH)

Colorectal Cancer Metastatic

Korea, Republic of, Canada, United States, Belgium, Spain, United Kingdom, France, Germany, Austria, Singapore, China, Italy, Poland
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Completed

Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer

Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma

United States
Stanford University

Completed

Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors

Primary Malignant Liver Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Unresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditions

United States
Methodist Health System

Completed

TheraSphere & Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer

Liver, Cancer of, Non-Resectable

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia in AIDS

HIV Infections | Pneumonia, Pneumocystis Carinii

United States
MedicalExcellence
Seoul National University Hospital; BTG International Inc.

Completed

A Study to Evaluate Efficacy and Safety of TheraSphere and Resection Combination Therapy in Patients With Single Large ((> 5cm, Long Diameter ) Hepatocellular Carcinoma : Exploratory Trial (Therasphere)

Carcinoma, Hepatocellular

Korea, Republic of
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Boston Scientific Corporation
BTG International Inc.

Completed

TheraSphere for the Treatment of Liver Metastases

Neoplasm Metastasis | Colorectal Cancer | Carcinoma, Neuroendocrine

United States
Boston Scientific Corporation
Biocompatibles UK Ltd

Terminated

RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry (READ90Y)

Liver Cancer

United States, Canada
Boston Scientific Corporation
Biocompatibles UK Ltd

Terminated

Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein (YES-P)

Hepatocellular Carcinoma

Spain, United Kingdom, United States, Belgium, France, Italy
Boston Scientific Corporation
Biocompatibles UK Ltd

Completed

A TheraSphere® Advanced Dosimetry Retrospective Global Study in HCC (TARGET)

Hepatocellular Carcinoma

United States, Switzerland, Germany, France, Italy, Netherlands, Saudi Arabia, Turkey
St. Joseph Hospital of Orange

Completed

A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®

Neoplasms | Hepatocellular Carcinoma | Hepatoma | Liver Tumors

United States
Stanford University
BTG International Inc.

Approved for marketing

A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma

Liver Cancer

United States
Northwestern University
BTG International Inc.

Terminated

Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®

Hepatocellular Carcinoma

United States
NewLink Genetics Corporation

Completed

Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers (NLG2111)

Healthy

United States
University of California, San Francisco

Terminated

Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Nicholas Fidelman, MD

Completed

Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases

Melanoma | Breast Cancer | Colorectal Neoplasms | Neuroendocrine Tumors | Cholangiocarcinoma
Center Eugene Marquis

Completed

Internal Radiation Therapy for Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry Versus Standard Dosimetry

Adenoma, Liver Cell

France
Center Eugene Marquis

Completed

Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma (MispheC)

Cholangiocarcinoma

France
Yale University

Completed

Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors

Liver Neoplasms

United States

Search clinical trials for: TheraSphere

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations